A phase 1, multicenter, open-label study to assess the effect of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) on QTc and pharmacokinetics in subjects with HER2-expressing metastatic and/or unresectable breast cancer

被引：3
|
作者：
Yamashita, Toshinari [1 ]
Shimomura, Akihiko [2 ]
Takano, Toshimi [3 ]
Sagara, Yasuaki [4 ]
Watanabe, Junichiro [5 ]
Tokunaga, Eriko [6 ]
Kikumori, Kunika [7 ]
Kamiyama, Emi [7 ]
Kamio, Takahiro [7 ]
Nakamura, Ryo [7 ]
Shinkai, Tetsu [8 ]
Takahashi, Shunji [9 ]
机构：
[1] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Toranomon Gen Hosp, Tokyo, Japan
[4] Hakuaikai Sagara Hosp, Social Med Corp, Kagoshima, Japan
[5] Shizuoka Canc Ctr, Shizuoka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Daiichi Sankyo Co Ltd, Tokyo, Japan
[8] Shonan Tobu Sougou Hosp, Kamakura, Kanagawa, Japan
[9] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P1-18-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-18-12
引用
收藏
页数：4
相关论文
共 50 条
  • [11] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01
    Yoshino, T.
    Siena, S.
    Di Bartolomeo, M.
    Raghav, K.
    Masuishi, T.
    Loupakis, F.
    Kawakami, H.
    Yamaguchi, K.
    Nishina, T.
    Fakih, M.
    Elez, E.
    Rodriguez, J.
    Ciardiello, F.
    Saxena, K.
    Yamamoto, E.
    Kobayashi, K.
    Bako, E.
    Okuda, Y.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S1275 - S1275
  • [12] A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1.
    Baselga, Jose
    Tamura, Kenji
    Yamashita, Toshinari
    Modi, Shanu
    Tokunaga, Eriko
    Ito, Yoshinori
    Iwata, Hiroji
    Charif, Mahmoud
    Lee, Caleb C.
    Sugihara, Masahiro
    Jikoh, Takahiro
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [13] A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
    Siena, Salvatore
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Fakih, Marwan
    Elez, Elena
    Rodriguez, Javier
    Ciardiello, Fortunato
    Saxena, Kapil
    Yamamoto, Eriko
    Bako, Emarjola
    Okuda, Yasuyuki
    Shahidi, Javad
    Grothey, Axel
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [14] A multicenter, multicohort, phase 2 study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing metastatic colorectal cancer - Trial in progress
    Yoshino, T.
    Siena, S.
    Dalal, R.
    Okuda, Y.
    Yamamoto, E.
    Grothey, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [15] A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer
    Hurvitz, S. A.
    Galsky, M. D.
    Shahidi, J.
    Zhang, G.
    Raza, S.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [16] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [17] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [18] [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs ado-trastuzumab emtansine (T-DM1) in subjects with HER2-positive, unresectable and/or metastatic breast cancer who previously received trastuzumab and a taxane: A phase 3, randomized trial (DESTINY-Breast03)
    Cortes, Javier
    Shahidi, Javad
    Lee, Caleb
    Zhang, Yufen
    Verma, Sunil
    CANCER RESEARCH, 2020, 80 (04)
  • [19] Exploratory biomarker analysis of DESTINY-CRC01, a phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd, DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC)
    Siena, S.
    Raghav, K.
    Masuishi, T.
    Yamaguchi, K.
    Nishina, T.
    Elez, E.
    Rodriguez, J.
    Chau, I.
    Di Bartolomeo, M.
    Kawakami, H.
    Suto, F.
    Kobayashi, K.
    Koga, M.
    Inaki, K.
    Kuwahara, Y.
    Takehara, I.
    Grothey, A.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2021, 32 : S532 - S532
  • [20] Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs TDM1 for HER2-positive breast cancer
    Verma, S.
    Shahidi, J.
    Lee, C.
    Wang, K.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2019, 30
12345